23andMe has filed documents with the SEC stating that it has raised $79 million of a $150 million round. The fundraising comes soon after the company revealed plans to dive into the drug development world, recruiting Genentech’s Richard Scheller as its chief scientific officer.
Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it’s already made a $50 million anchor investment in. …read more […]